LogicBio Therapeutics, Inc. Research and Development Expense
LogicBio Therapeutics, Inc. reported Research and Development Expense of $5.05 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-11-14
- LogicBio Therapeutics, Inc. research and development expense for the quarter ending 2022-09-30 was $5.05M, a 35.29% decline year-over-year.
- LogicBio Therapeutics, Inc. research and development expense for the quarter ending 2022-06-30 was $4.83M, a 33.42% decline year-over-year.
- LogicBio Therapeutics, Inc. research and development expense for the quarter ending 2022-03-31 was $5.64M, a 12.12% decline year-over-year.
- LogicBio Therapeutics, Inc. research and development expense for the quarter ending 2021-12-31 was $6.69M, a 59.48% increase year-over-year.
- LogicBio Therapeutics, Inc. research and development expense for fiscal 2021 was $28.17M, a 23.80% increase from fiscal 2020.
- LogicBio Therapeutics, Inc. research and development expense for fiscal 2020 was $22.75M, a 25.78% decline from fiscal 2019.
- LogicBio Therapeutics, Inc. research and development expense for fiscal 2019 was $30.66M, a 176.70% increase from fiscal 2018.
- LogicBio Therapeutics, Inc. research and development expense for fiscal 2018 was $11.08M, a 211.38% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $5.05M 10-Q · filed 2022-11-14 | $9.88M derived: sum of 2 quarters · filed 2022-11-14 | $15.52M 10-Q · filed 2022-11-14 | $22.21M derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | $4.83M 10-Q · filed 2022-08-15 | $10.47M 10-Q · filed 2022-08-15 | $17.16M derived: sum of 3 quarters · filed 2022-08-15 | $24.97M derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-03-31 | $5.64M 10-Q · filed 2022-05-16 | $12.33M derived: sum of 2 quarters · filed 2022-05-16 | $20.13M derived: sum of 3 quarters · filed 2022-11-14 | $27.39M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-12-31 | $6.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $14.49M derived: sum of 2 quarters · filed 2022-11-14 | $21.75M derived: sum of 3 quarters · filed 2022-11-14 | $28.17M 10-K · filed 2022-03-04 |
| 2021-09-30 | $7.81M 10-Q · filed 2022-11-14 | $15.06M derived: sum of 2 quarters · filed 2022-11-14 | $21.48M 10-Q · filed 2022-11-14 | $25.68M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $7.26M 10-Q · filed 2022-08-15 | $13.68M 10-Q · filed 2022-08-15 | $17.87M derived: sum of 3 quarters · filed 2022-08-15 | $23.36M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $6.42M 10-Q · filed 2022-05-16 | $10.61M derived: sum of 2 quarters · filed 2022-05-16 | $16.10M derived: sum of 3 quarters · filed 2022-05-16 | $22.00M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $9.69M derived: sum of 2 quarters · filed 2022-03-04 | $15.58M derived: sum of 3 quarters · filed 2022-03-04 | $22.75M 10-K · filed 2022-03-04 |
| 2020-09-30 | $5.49M 10-Q · filed 2021-11-15 | $11.39M derived: sum of 2 quarters · filed 2021-11-15 | $18.56M 10-Q · filed 2021-11-15 | $26.94M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $5.89M 10-Q · filed 2021-08-09 | $13.07M 10-Q · filed 2021-08-09 | $21.45M derived: sum of 3 quarters · filed 2021-08-09 | $30.30M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $7.17M 10-Q · filed 2021-05-10 | $15.55M derived: sum of 2 quarters · filed 2021-05-10 | $24.41M derived: sum of 3 quarters · filed 2021-05-10 | $32.34M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $8.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $17.24M derived: sum of 2 quarters · filed 2021-03-15 | $25.17M derived: sum of 3 quarters · filed 2021-03-15 | $30.66M 10-K · filed 2021-03-15 |
| 2019-09-30 | $8.86M 10-Q · filed 2020-11-09 | $16.79M derived: sum of 2 quarters · filed 2020-11-09 | $22.28M 10-Q · filed 2020-11-09 | $27.24M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $7.93M 10-Q · filed 2020-08-10 | $13.42M 10-Q · filed 2020-08-10 | $18.39M derived: sum of 3 quarters · filed 2020-08-10 | $20.82M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $5.49M 10-Q · filed 2020-05-11 | $10.45M derived: sum of 2 quarters · filed 2020-05-11 | $12.88M derived: sum of 3 quarters · filed 2020-05-11 | $15.11M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $4.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $7.40M derived: sum of 2 quarters · filed 2020-03-16 | $9.62M derived: sum of 3 quarters · filed 2020-03-16 | $11.08M 10-K · filed 2020-03-16 |
| 2018-09-30 | $2.43M 10-Q · filed 2019-11-12 | $4.66M derived: sum of 2 quarters · filed 2019-11-12 | $6.11M 10-Q · filed 2019-11-12 | $8.20M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $2.23M 10-Q · filed 2019-08-13 | $3.68M 10-Q · filed 2019-08-13 | $5.77M derived: sum of 3 quarters · filed 2019-08-13 | $6.35M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $1.46M 10-Q · filed 2019-05-14 | $3.55M derived: sum of 2 quarters · filed 2019-05-14 | $4.13M derived: sum of 3 quarters · filed 2019-05-14 | |
| 2017-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $2.67M derived: sum of 2 quarters · filed 2019-04-01 | $3.56M 10-K · filed 2019-04-01 | |
| 2017-09-30 | $580.00K 10-Q · filed 2018-12-03 | $1.47M 10-Q · filed 2018-12-03 |